FilingReader Intelligence
Fudan-Zhangjiang Bio-Pharma sees significant profit decline in 2024
February 27, 2025 at 05:03 PM UTC•By FilingReader AI
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (HKEX:1349) announced preliminary annual results for 2024, revealing a substantial decline in profitability. Net profit attributable to shareholders of the listed company decreased by 63.42% to RMB 39.7 million, compared to RMB 108.6 million in the previous year. The company's operating profit plummeted by 97.53% to RMB 2.39 million, while total profit fell by 94.40% to RMB 5.46 million.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1349•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Fudan-Zhangjiang Bio-PharmaLtd publishes news
Free account required • Unsubscribe anytime